Johnson & Johnson (NYSE:JNJ) Shares Sold by Anchor Capital Advisors LLC

Anchor Capital Advisors LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 7.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 136,737 shares of the company’s stock after selling 11,418 shares during the period. Anchor Capital Advisors LLC’s holdings in Johnson & Johnson were worth $21,432,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Greatmark Investment Partners Inc. raised its holdings in shares of Johnson & Johnson by 4.2% during the 4th quarter. Greatmark Investment Partners Inc. now owns 92,118 shares of the company’s stock valued at $14,439,000 after buying an additional 3,678 shares during the period. Birchcreek Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 1.3% in the fourth quarter. Birchcreek Wealth Management LLC now owns 5,576 shares of the company’s stock valued at $874,000 after purchasing an additional 74 shares during the period. Choreo LLC grew its holdings in Johnson & Johnson by 35.6% during the 4th quarter. Choreo LLC now owns 54,647 shares of the company’s stock valued at $8,565,000 after purchasing an additional 14,358 shares in the last quarter. Gilbert & Cook Inc. increased its stake in Johnson & Johnson by 3.3% during the 4th quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock worth $1,428,000 after buying an additional 288 shares during the period. Finally, Eagle Wealth Strategies LLC acquired a new position in Johnson & Johnson in the 4th quarter worth $348,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $149.27 on Friday. The company has a 50-day moving average price of $154.19 and a two-hundred day moving average price of $155.02. The stock has a market cap of $359.25 billion, a price-to-earnings ratio of 9.31, a price-to-earnings-growth ratio of 2.46 and a beta of 0.55. The company has a current ratio of 1.17, a quick ratio of 0.91 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. During the same period last year, the firm earned $2.68 EPS. The firm’s revenue was up 2.3% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be paid a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. This represents a $4.96 annualized dividend and a yield of 3.32%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 29.68%.

Analyst Ratings Changes

JNJ has been the topic of a number of analyst reports. Royal Bank of Canada dropped their target price on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 17th. Bank of America cut their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price target for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Morgan Stanley cut their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 17th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $175.86.

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.